No quarterly revenue total was found in BRIACELL THERAPEUTICS CORP.'s SEC filings.
Briacell Therapeutics Corp. (BCTX) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$6.0 million.
Revenue
—
Net income
$-12.32M
-52.3% vs year-ago quarter
Operating cash flow
$-5.96M
+26.7% vs year-ago quarter
Free cash flow
$-5.96M
+16.6% vs prior quarter
EPS
$-1.51
+83.8% vs year-ago quarter
Dividend per share
None
Shares outstanding
8.73M
+363.5% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BCTX (Nasdaq), BCTXL (Nasdaq), BCTXZ (Nasdaq)
- Fiscal year ends
- July 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- West Vancouver, British Columbia, Canada
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1610820
- Former names
- Ansell Capital Corp. (until Jun 20, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q4 FY2026 Jul 31, 2026 |
Q3 FY2026 Apr 30, 2026 |
Q2 FY2026 Jan 31, 2026 |
Q1 FY2026 Oct 31, 2025 |
Q4 FY2025 Jul 31, 2025 |
|---|---|---|---|---|---|
| Operating income | -$12.6M | -$7.6M | -$7.5M | -$8.3M | -$8.6M |
| Net income | -$12.3M | -$7.2M | -$7.2M | -$8.2M | -$8.1M |
| Diluted EPS | -$1.51 | -$0.99 | -$2.58 | -$4.35 | -$9.29 |
| Operating cash flow | -$6.0M | -$7.0M | -$8.0M | -$7.7M | -$8.1M |
| Free cash flow | -$6.0M | -$7.1M | — | — | — |
| Total assets | $23.6M | $27.1M | $33.6M | $13.1M | $21.6M |
| Stockholders' equity | $15.6M | $23.4M | $30.2M | $9.4M | $17.3M |
| Cash and investments | $20.5M | $22.8M | $29.9M | $10.2M | $17.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-K | Annual report | Oct 28, 2026 | Jul 31, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 26, 2026 | Jun 26, 2026 |
| 10-Q | Quarterly report | Jun 9, 2026 | Apr 30, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Jun 3, 2026 | May 31, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 31, 2026 | Mar 31, 2026 |
| 10-Q | Quarterly report | Mar 10, 2026 | Jan 31, 2026 |
All 324 Briacell Therapeutics Corp. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.